This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ylikoski, A. Articles by Lövgren, T. Search for Related Content PubMed PubMed Citation Articles by Ylikoski, A. Articles by Lövgren, T.

JMD 2001, Vol. 3, No. 3
Copyright © 2001 American Society for Investigative Pathology & Association for Molecular Pathology

Simultaneous Quantification of Human Glandular Kallikrein 2 and Prostate-Specific Antigen mRNAs in Peripheral Blood from Prostate Cancer Patients

Alice Ylikoski^*, Matti Karp^*, Kim Pettersson^*, Hans Lilja and Timo Lövgren^*

From the Department of Biotechnology, * University of Turku, Turku, Finland; and the Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, University Hospital Malmo, Malmo, Sweden

We present a multiplexed and internally calibrated quantitative reverse transcription-PCR (QRT-PCR) assay to detect human glandular kallikrein 2 (hK2) and prostate-specific antigen (PSA) transcripts in blood samples from healthy subjects and prostate cancer (PC) patients. The assay detected 50 copies of hK2 and PSA mRNA, and 1 PSA- and 10 hK2-expressing LNCaP cells in the presence of 2.5 x 10⁶ PSA- and hK2-negative cells. In PC patients, 20 of 25 and 19 of 25 gave detectable PSA and hK2 mRNAs, respectively. Number of hK2 mRNA copies was significantly higher than that of PSA mRNA copies in patients with biochemically progressive (P = 0.02) PC, and with locally advanced and metastasized (P = 0.004) PC. Patients with rapidly progressive and hormone refractory PC gave detectable hK2 mRNA only in 2 of 8 and PSA mRNA in 3 of 8 patients. Neither PSA nor hK2 mRNAs were detected in 16 healthy subjects. PSA and hK2 discriminated PC patients with biochemically progressive and advanced disease from the controls and from the aggressive distant metastatic disease. The assay provides a reliable quantification of the number of hK2 and PSA mRNA copies, allows to discriminate PC cases from healthy subjects, and offers a tool for further studies on molecular staging of PC.

This article has been cited by other articles:

				P. Helo, A. M. Cronin, D. C. Danila, S. Wenske, R. Gonzalez-Espinoza, A. Anand, M. Koscuiszka, R.-M. Vaananen, K. Pettersson, F. K.-H. Chun, et al. Circulating Prostate Tumor Cells Detected by Reverse Transcription-PCR in Men with Localized or Castration-Refractory Prostate Cancer: Concordance with CellSearch Assay and Association with Bone Metastases and with Survival Clin. Chem., April 1, 2009; 55(4): 765 - 773. [Abstract] [Full Text] [PDF]

				T. Steuber, A. J. Vickers, A. M. Serio, V. Vaisanen, A. Haese, K. Pettersson, J. A. Eastham, P. T. Scardino, H. Huland, and H. Lilja Comparison of Free and Total Forms of Serum Human Kallikrein 2 and Prostate-Specific Antigen for Prediction of Locally Advanced and Recurrent Prostate Cancer Clin. Chem., February 1, 2007; 53(2): 233 - 240. [Abstract] [Full Text] [PDF]

				S. M. O'Hara, J. G. Moreno, D. R. Zweitzig, S. Gross, L. G. Gomella, and L. W.M.M. Terstappen Multigene Reverse Transcription-PCR Profiling of Circulating Tumor Cells in Hormone-Refractory Prostate Cancer Clin. Chem., May 1, 2004; 50(5): 826 - 835. [Abstract] [Full Text] [PDF]

				A. Ylikoski, K. Pettersson, J. Nurmi, K. Irjala, M. Karp, H. Lilja, T. Lovgren, and M. Nurmi Simultaneous Quantification of Prostate-specific Antigen and Human Glandular Kallikrein 2 mRNA in Blood Samples from Patients with Prostate Cancer and Benign Disease Clin. Chem., August 1, 2002; 48(8): 1265 - 1271. [Abstract] [Full Text] [PDF]